Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: the case for.

× No keyword cloud information.

30 in total

1. Kinetics of viral clearance in plasma, peripheral blood mononuclear cells and lymph nodes.

Authors: A Lafeuillade; A Djediouane; C Poggi; N Profizi; O Costes; C Tamalet
Journal: AIDS Date: 1996-06 Impact factor: 4.177

2. Surrogate endpoints in clinical trials: definition and operational criteria.

Authors: R L Prentice
Journal: Stat Med Date: 1989-04 Impact factor: 2.373

3. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials.

Authors: D Y Lin; M A Fischl; D A Schoenfeld
Journal: Stat Med Date: 1993-05-15 Impact factor: 2.373

4. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study.

Authors: G Liuzzi; A Chirianni; M Clementi; P Bagnarelli; A Valenza; P T Cataldo; M Piazza
Journal: AIDS Date: 1996-12 Impact factor: 4.177

5. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.

Authors: L D Saravolatz; D L Winslow; G Collins; J S Hodges; C Pettinelli; D S Stein; N Markowitz; R Reves; M O Loveless; L Crane; M Thompson; D Abrams
Journal: N Engl J Med Date: 1996-10-10 Impact factor: 91.245

6. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors: S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal: N Engl J Med Date: 1996-10-10 Impact factor: 91.245

7. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

Authors: D A Katzenstein; S M Hammer; M D Hughes; H Gundacker; J B Jackson; S Fiscus; S Rasheed; T Elbeik; R Reichman; A Japour; T C Merigan; M S Hirsch
Journal: N Engl J Med Date: 1996-10-10 Impact factor: 91.245

8. HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.

Authors: A N Phillips; J J Eron; J A Bartlett; M Rubin; J Johnson; S Price; P Self; A M Hill
Journal: AIDS Date: 1996-07 Impact factor: 4.177

9. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.

Authors: S Choi; S W Lagakos; R T Schooley; P A Volberding
Journal: Ann Intern Med Date: 1993-05-01 Impact factor: 25.391

10. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.

Authors: R W Coombs; S L Welles; C Hooper; P S Reichelderfer; R T D'Aquila; A J Japour; V A Johnson; D R Kuritzkes; D D Richman; S Kwok; J Todd; J B Jackson; V DeGruttola; C S Crumpacker; J Kahn
Journal: J Infect Dis Date: 1996-10 Impact factor: 5.226

1 in total

Review 1. HIV, HCV and HBV: A Review of Parallels and Differences.

Authors: Maria C Leoni; Andrew Ustianowski; Hamzah Farooq; Joop E Arends
Journal: Infect Dis Ther Date: 2018-09-04

1 in total